The essential event that initiated the cloning of TPO was the identification of its receptor: c-Mpl. 6 Human c-Mpl receptor is a transmembrane receptor that belongs to the cytokine receptor superfamily as characterized by its double hemopoietin receptor domain with 2 pairs of conserved cysteine residues. The expression of c-Mpl appears to be restricted to platelets, megakaryoctes, and CD34+ progenitor cells. Thrombopoietin, TPO, a 353 amino acid cytokine, is a primary regulator of platelet production that was cloned recently. A target-mediated (platelet receptors) pharmacokinetic model was developed to characterize the disposition of TPO. Receptor-mediated endocytosis was assigned as the major elimination pathway in the model. A nonspecific binding compartment was also incorporated into the model. TPO concentration vs time profiles from a published phase 1 and 2 clinical trial were used to apply this model. Noncompartmental analysis demonstrated that TPO exhibits nonlinear kinetics. The proposed model captured the concentration-time profiles relatively well. The first-order internalization rate constant was estimated as 0.1 h Upon binding to its receptor and undergoing subsequent cellular signal transduction processes such as tyrosine phosphorylation of TPO receptor, TPO stimulates the proliferation, differentiation, and maturation of megakaryocytes. In vitro studies have demonstrated that TPO increases the ploidy and number of megakaryocytes as well as stimulates the expression of platelet-specific markers such as Ib and IIb/IIIa and promotes endomitosis in megakaryocytes. TPO is also a potent megakaryocyte colony-stimulating factor in the early stage of megakaryocytopoiesis, capable of inducing the proliferation of megakaryocyte progenitor cells. 8 In addition, TPO acts in synergy with erythropoietin to promote the growth of erythroid progenitor cells. 9 In the presence of early-acting cytokines such as IL-3 or steel factors, it exhibits both proliferative and differentiative effects on primitive hematopoietic stem cells.
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Thrombopoietin, TPO, a 353 amino acid cytokine, is a primary regulator of platelet production that was cloned recently. A target-mediated (platelet receptors) pharmacokinetic model was developed to characterize the disposition of TPO. Receptor-mediated endocytosis was assigned as the major elimination pathway in the model. A nonspecific binding compartment was also incorporated into the model. TPO concentration vs time profiles from a published phase 1 and 2 clinical trial were used to apply this model. Noncompartmental analysis demonstrated that TPO exhibits nonlinear kinetics. The proposed model captured the concentration-time profiles relatively well. The first-order internalization rate constant was estimated as 0.1 h , rendering the equilibrium dissociation constant K d as 45.5 pM. This model may be relevant to other therapeutic agents with receptor-mediated endocytotic disposition.
Upon binding to its receptor and undergoing subsequent cellular signal transduction processes such as tyrosine phosphorylation of TPO receptor, TPO stimulates the proliferation, differentiation, and maturation of megakaryocytes. In vitro studies have demonstrated that TPO increases the ploidy and number of megakaryocytes as well as stimulates the expression of platelet-specific markers such as Ib and IIb/IIIa and promotes endomitosis in megakaryocytes. TPO is also a potent megakaryocyte colony-stimulating factor in the early stage of megakaryocytopoiesis, capable of inducing the proliferation of megakaryocyte progenitor cells. 8 In addition, TPO acts in synergy with erythropoietin to promote the growth of erythroid progenitor cells. 9 In the presence of early-acting cytokines such as IL-3 or steel factors, it exhibits both proliferative and differentiative effects on primitive hematopoietic stem cells.
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The previous results from in vitro studies have been confirmed in preclinical studies. Administration of TPO to normal mice caused a 4-fold rise in platelet count, along with a 20-fold increase in marrow colony-forming unitmegakaryocytes and a 10-fold increase in megakaryocytes. Panhematopoietic effects were also found. 11 In myelosuppressed animal models, TPO ameliorates thrombocytopenia via increasing the platelet count nadir and accelerating platelet recovery.
INTRODUCTION
During the process of platelet production, hematopoietic growth factors play a key regulatory role. Among them, thrombopoietin (TPO) is the primary regulator in megakaryocytic lineage. Although the existence of TPO was suggested early in the 1960s, it was not identified until 1994 when 5 different groups successfully cloned the cDNA of TPO independently. [1] [2] [3] [4] [5] TPO is produced predominantly in the liver by hepatocytes. Other organs expressing TPO mRNA are bone marrow, kidney, brain, testis, and spleen. [13] [14] The circulating level of free TPO is inversely related to the platelet count. 15 By analogy to the transcriptional regulation of erythropoietin in anemia, 16 it was suggested that circulating TPO concentrations might be regulated by the TPO gene expression level. However, in animals with severe thrombocytopenia, endogenous TPO mRNA level is normal. 17 As an alternative, the TPO level might be regulated by binding to its receptors on platelets. In thrombocytopenic animals, plasma TPO concentrations drop soon after platelet transfusion and rise after platelet count drops.
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Figure 1.
Receptor-mediated disposition model for TPO kinetics. Free TPO in plasma (TPO f , V p ) binds to its cMpl receptor on platelet surface (R p ) to form drugreceptor complex (TPO p ) and is eliminated at the firstorder rate (k el ). TPO p dissociates back to free TPO and receptor or is internalized into platelet (k int ). TPO f also has nonspecific tissue binding (A TPOn , V n ).
The concept of target-mediated drug disposition has been introduced previously 18 and explored further recently. 19 In this study, we applied a target-mediated drug disposition pharmacokinetic model for TPO and investigated the nonlinear kinetic properties of TPO kinetics.
MATERIALS AND METHODS
Theoretical
Based on its physiology, a mechanistic pharmacokinetic model for TPO is proposed and shown in Figure 1 . Circulating free TPO (TPO f ) and c-Mpl receptors (R p ) on the platelet surface are constantly produced at zero-order rates denoted by k t and k r . The whole model is composed of 2 major binding components to account for TPO disposition. One component is that TPO binds to cMpl receptor on platelet surface. This mechanism is described by the second-order association constant k on and the first-order dissociation constant k off (K d = k off /k on ). This binding process is capacity limited, with the equilibrium constant K d ranging between 100 and 846 pM. [20] [21] [22] After free TPO in the circulation binds to c-Mpl, a drug-receptor complex (TPO p ) is formed, which then dissociates back to free drug and receptor. This complex can also be internalized into the platelet and degraded by lysosomes. 21 The internalization is described by the firstorder constant k int . This process, also known as receptormediated endocytosis, reflects the major elimination pathway of TPO. After internalization and degradation, the c-Mpl receptor will not recycle back to the platelet surface. [20] [21] A nonspecific TPO binding component (A TPOn ) is also present in the model to which TPO nonspecifically binds (k fn ) and dissociates (k nf ) at first-order rates. The nonspecific binding sites could be located in peripheral tissues. 17 In addition, we postulate the first-order TPO elimination (k el ) that can be attributed to renal and hepatic TPO clearances. However, this process is considered secondary to TPO receptor binding and internalization. The whole model is described by the following equations:
Since the binding of TPO to the c-Mpl receptor would stimulate the production of platelets, the production rate of free receptor would be concomitantly increased. The model assumes that this production rate is proportional to the concentration of drug-receptor complex (TPO p ), which is reflected by the equation below:
where TPO p,0 represents the baseline level of TPO bound to c-Mpl. Equation 1 is driven by minimizing of the number of parameters that would be necessary if a more physiological saturable stimulation of the c-Mpl production was introduced.
where V p denotes the plasma volume.
The endogenous TPO concentrations were set as the initial condition for TPO f (TPO f,0 = 1.4 pM). 23 The initial value of TPO bound to c-Mpl receptor (TPO p,0 ), nonspecific binding sites (A TPOn,0 ) and the zero-order rate con-stants k t and k r can be calculated from the steady-state equations as follows:
where R p,0 denotes the baseline c-Mpl plasma receptor concentration, which can be identified as the binding capacity of endogenous receptors. Equation 9 is the consequence of the simplified stimulatory mechanism described by Equation 1. Equations 6-9 hold only for the baseline (predose) conditions.
The model was applied to literature data. The data sets were obtained from the original article by Vadhan-Raj et al 23 via data digitization using the Sigma Scan program (Jandel Scientific Inc, San Rafeal, CA). A phase 1 and 2 cohort clinical study was performed by the investigators, and a single dose of recombinant human TPO was given intravenously to 12 patients with sarcoma (7 men and 5 women) prior to chemotherapy. Three patients were assigned to each of 4 dose levels (0.3, 0.6, 1.2, and 2.4 μg/kg of body weight). The free TPO concentrations in plasma were measured up to 5 days. Group mean data were used in the data analysis.
In order to develop mass balance equations, the concentrations of TPO were transferred from ng/mL to pM assuming the molecular weight of TPO was 70 kD. The average body weight of 70 kg was used in both noncompartmental and compartmental analysis.
Noncompartmental Analysis
A noncompartmental approach was used to identify the nonlinearity of TPO kinetics. Since TPO has a baseline level when no drug is administered, the baseline value (1.4 pM) must be subtracted from the measured concentration to carry out noncompartmental analysis. The noncompartmental analysis was performed using WinNonlin Professional release 2.1 (Pharsight Corp, Apex, NC). The C max , T max , steady-state volume of distribution (V ss ), apparent clearance, terminal slope (Ȝ z ), terminal half-life, total area under the curve (AUC), area under the moment TPO f versus time curve (AUMC), and mean residence time (MRT) were calculated. The C max and T max values were read directly from original data graphs. Terminal half-life was calculated as 0.693/Ȝ z . The AUC and AUMC were calculated by the log-linear trapezoidal method with terminal phase extrapolation. The analysis was performed separately for different doses.
In order to analyze the linearity of TPO pharmacokinetics, dose normalization and the rule of superpositioning were used for evaluation. The dose-normalized concentration vs time and total AUC vs dose graphs were the major diagnostic tools.
Nonlinear Regression Analysis
The proposed pharmacokinetic model was simultaneously fitted to 4 dose data sets. The nonlinear regression was performed using ADAPT II release 4 program (Biomedical Simulations Resource, University of Southern California, Los Angeles, CA). 24 The maximum likelihood objective function was used to obtain system parameter estimates and the variance model shown below was applied:
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The initial estimates of k on , k off , and k int , were obtained from the study by Li et al. 19 In the model, k on and k off were estimated independently. The V p was fixed as plasma volume of 3 L. Then TPO p,0 , A TPOn,0 , k t , and k r were calculated from Equations 6, 7, 8, and 9 as secondary parameters. The fitted parameters were k on , k off , k int , k nf , k fn , and R p,0 .
RESULTS
Noncompartmental Analysis
Two graphical methods are used to evaluate the nonlinearity of TPO disposition. First, dose normalized TPO f concentrations are plotted vs time for each dose ( Figure  2) . Judging by the rule of superposition, nonlinear phar- macokinetics could be concluded by visual inspection because the plots from the 4 dose levels do not converge into one. Second, total AUC for each of the 4 doses are plotted vs dose. Nonlinear pharmacokinetics is also indicated by the curvature of the plotted line (Figure 3 ). Parameters obtained from noncompartmental analysis are summarized in Table 1 . As dose increased, Ȝ z increased accordingly and total AUC increased in a more than dose-proportional manner, while clearance (CL) and V ss go to the opposite direction.
Nonlinear Regression Analysis
The model Equations 2 through 5 were simultaneously fitted to plasma-free TPO data and the fittings are shown in Figure 4 . The pharmacokinetic profile of TPO exhibits multiexponential behavior. The estimated parameters are shown in Table 2 . The model allowed the estimation of the binding parameters k on and k off as well as internalization parameter k int , which are of major interest. They were estimated with a good precision with the coefficient of variation (CV) not exceeding 37%. The estimated k on value is similar with results from in-vitro binding analysis. 21 In addition, the endogenous plateletbinding capacity R p,0 was estimated as 164.0 pM, which yielded the calculated number of receptors per platelet 398, if 250 × 10 9 platelets/L is assumed. The internalization half-life calculated from k int was 6.9 hours. The baseline values of A TPOn,0 and TPO p,0 were estimated as 11.11 pmol (CV = 13.6%) and 4.87 pM (CV = 15.8%). The zero-order production rate for endogenous free TPO (k t ) and c-Mpl receptor k r were both estimated as 0.49 pM/h (CV = 10.7%). The elimination rate k el was fixed at 0. The simultaneous fittings resulted in partial overestimation of the 0.6 and underestimation of the 1.2 μg/kg dose group, whereas other dose groups were fitted reasonably well. Overall, a good agreement between the observed and predicted data was observed.
DISCUSSION
Model Building
TPO metabolism and elimination have been extensively studied in vitro, and it is widely accepted that binding to c-Mpl receptors on platelets is the major elimination pathway of TPO. It has also been demonstrated that there is a reciprocal relationship between plasma TPO level and platelet mass. With limited numbers of c-Mpl receptors residing on platelet and megakaryocyte surfaces, if a high dose of TPO is administered, the concentration-time profile of TPO would exhibit capacitylimited and nonlinear characteristics. Such behavior could be categorized as target-mediated drug disposition, a term introduced by Levy 25 to describe a process in which drug binds to its specific receptor and subsequent metabolism and degradation become its primary route of elimination. The proposed pharmacokinetic model is built on such theory to characterize TPO disposition. We adopted the pharmacokinetic model of target-mediated disposition introduced by Mager at al. 19 The only change we made was the incorporation into our model of the free receptor compartment R p , whereas originally the free receptors were expressed as R max -DR, where R max denoted the total concentration of receptors and DR was the concentration of the drug-target complex. The free receptors R p and bound receptors TPO p in our model have independent kinetics, and the total number of receptors is the sum of these 2:
The binding of TPO to its receptor c-Mpl is a crucial component of the whole model. The TPO binding properties have been studied intensively with a reported binding capacity ranging from 25 to 225 receptors per platelet and binding constant K d values ranging from 100 to 846 pM indicating a very high binding affinity. 20 In addition to platelets, c-Mpl is also expressed on megakaryocytes and to a much less extent, on progenitor cells such as CD34+ cells. 7 The binding of TPO to receptors on these cells is not included in the model for several reasons. For progenitor cells, the expression of cMpl on these cells is very low and their contribution to TPO kinetics is insignificant. For megakaryocytes, the expression of c-Mpl is also minor compared with platelets, and it will not affect the general pharmacokinetic profile of TPO very much. Another reason is that megakaryocyte is a giant cell with heterogeneous ploidy in nature. 26 The receptor number on one megakaryocyte is distinct in relation to others. However, since the binding of TPO to megakaryocytes is the initiating event that stimulates the production of platelets, this compartment should be incorporated into the model if the pharmacodynamic effect of TPO is also of interest.
Upon binding, the drug-receptor complexes are susceptible to internalization into platelets and degradation by lysosomes. Such a phenomenon is called receptormediated endocytosis, which constitutes the principal pathway for the irreversible removal of TPO from the body. After degradation, the receptors would not recycle back to the platelet surface.
As a glycoprotein with 353 amino acids (70 kD), TPO is predominantly distributed in the circulation system. The high molecular weight also precludes its transport to peripheral tissues extensively. Thus the volume for the free TPO compartment is fixed to be the plasma volume (3 L for a normal person of weight 70 kg). TPO has a very long half-life in the systemic circulation. The 177 amino acid carboxyl terminal domain retaining several N-linked glycosylation sites are believed to stabilize TPO and prevent it from degradation by proteases and other enzymes. 12 It might be inferred that hepatic metabolism and renal clearance have minor contributions to total TPO elimination. Large molecular weight limits the renal elimination of TPO because a macromolecule with a molecular weight larger than 69 kD is unlikely to traverse the glomerulus. 27 The C-terminal glycosylation also prevents the molecule from readily transporting into liver. Therefore, the elimination directly from the free TPO compartment is ignored (k el = 0).
A nonspecific binding compartment is also included in the model. Fielder et al 17 have demonstrated that TPO is distributed into several tissues, especially highly perfused tissues, in mice after exogenous TPO administration. Consequently, we found it is necessary to incorporate this compartment into the model.
The other feature of this model is the presence of a stimulation process on c-Mpl receptor production. Based on its mechanism of action, the input of exogenous TPO would increase the production of platelets. Therefore, more receptors would be available for binding after drug administration. The extent of platelet production increase is dependent on how much TPO has bound to c-Mpl receptors on megakaryocytes. It has been reported that c-Mpl receptors on platelets and megakaryocytes have the same binding characteristics. 17 To avoid addition of the megakaryocyte compartment into the model, a simplistic assumption was made that the TPO bound to receptors on megakaryocytes is reflected as part of TPO bound to platelets. In terms of the pattern for a stimulation process, a direct proportion of TPO p /TPO p,0 was used. Such a stimulation term is highly sensitive to the concentration change of TPO p and can produce a sharp increase of production rate. It could be otherwise modified to a slow stimulation term when a more delayed effect is expected. The nonlinear Hill equation would be the best candidate for such a process, since for higher TPO concentrations, a saturation of the stimulus can be expected. However, to minimize the number of model parameters, the linear stimulation was assumed. By controlling the nature of the stimulation process, we can get various pharmacokinetic profiles of TPO bound to platelets and/or megakaryocytes. Such information could be used as the driving force for the indirect response model 28 or life-span model 29 established to characterize the pharmacodynamic effect of TPO.
A clinical data set from Vadhan-Raj et al 23 was used to evaluate the proposed model. The patients recruited in the clinical study had normal hematopoietic function before treatment. Their blood cell counts, with the exception of platelets, were before and remained within the normal limits after TPO treatment. Only platelet levels were elevated by day 21 but before the initiation of chemotherapy. Hematological alterations can be observed in as many as 40% of patients with soft tissue sarcomas prior to chemotherapy 30 . Thrombocytosis can occur in 15% of patients. The frequency of hematological abnormalities increases in patients with advanced tumors. The study encompassed 4 doses varying from 0.3 to 2.4 μg/kg. These levels are sufficiently large for assessing nonlinear pharmacokinetics drug modeling.
Noncompartmental Analysis
After drug input, the plasma-free TPO concentrations reach the maximum value and increase in a dose-related manner. Then the concentrations drop very quickly for the 2 lower doses; this is less apparent for the 2 higher doses indicating a certain elimination or distribution threshold has been approached for high doses. The terminal slope increases as the dose increases, rendering the terminal half-life ranging from 18 to 35 hours. The enzyme-linked immunosorbent assay (ELISA) quantitative method for TPO measurement has a general detection limit at 0.15 ng/mL, which is close to the TPO endogenous level. 31 The concentrations for the terminal phase for the 2 lower doses may have already reached baseline, thus the terminal half-life may be overestimated. The apparent drug clearance is low for high doses, indicating the elimination processes may have been saturated at high dose levels. The apparent steadystate volume of distribution decreases as well when the dose is increased confirming nonlinearity. Furthermore, it has also been demonstrated that saturable plasma protein binding is insignificant regarding specific drug target binding or tissue binding. 32 However, caution should be kept in mind when interpreting noncompartmental results because the CL and V ss calculations may be erroneous when a nonlinear elimination process is involved. 33 The dose dependence of CL and V ss is a consequence of the nonlinear receptor-mediated kinetics. This phenomenon has been analyzed elsewere. 19 Two graphical techniques were used to identify the nonlinearity of TPO pharmacokinetics. When the concentrations divided by dose were plotted vs time for each dose, the lack of superposition for the 4 doses indicates the existence of dose-dependent pharmacokinetics. When AUC values were plotted vs dose, it was observed that AUC values were not proportional to dose. This finding also indicates nonlinear pharmacokinetics. 34 Moreover, an increase in AUC, which is greater than dose proportional is very much likely attributable to saturation in elimination. 35 
Nonlinear Regression Analysis CONCLUSION
A target-mediated endocytosis disposition model has been established to account for the nonlinear characteristics of TPO pharmacokinetics. The model well captured the concentration-time profiles of the clinical data set after single-dose administration of TPO in patients with sarcoma prior to chemotherapy. The determined binding and internalization parameters are comparable with reported results from in vitro studies. Future studies will be focused on the application of the present model to the modeling of pharmacokinetic (free TPO plasma concentration) and pharmacodynamic data (platelet count) simultaneously.
The proposed model was employed to describe the clinical data set. The predicted profile captured the data points for all dose levels relatively well. The reported parameters had relatively low coefficients of variation. The estimated k on value was similar to the initial estimate taken from literature. 21 The calculated K d value (45.5 pM) from estimated k on and k off value was, however, lower than the reported value (100-846 pM). There are several possible reasons that could account for this discrepancy. The K d value is often obtained in vitro. The binding study of Li et al 21 was performed in a 25°C system, which is different from the normal physiological condition. Also in their study, they found that temperature greatly affected the clearance of TPO. TPO clearance at 4°C was only 2% of that at 37°C.
